Managennent of latent Mycobacterium tuberculosis infection: WHO guidelines for Low tuberculosis burden countries

被引：465

作者：

Getahun, Haileyesus ^{[1
]}

Matteelli, Alberto ^{[1
]}

Abubakar, Ibrahim ^{[2
,3
]}

Aziz, Mohamed Abdel ^{[4
]}

Baddeley, Annabel ^{[1
]}

Barreira, Draurio ^{[5
]}

Den Boon, Saskia

Borroto Gutierrez, Susana Marta ^{[6
]}

Bruchfeld, Judith ^{[7
,8
]}

Burhan, Edina ^{[9
,10
]}

Cavalcante, Solange ^{[11
]}

Cedillos, Rolando ^{[12
]}

Chaisson, Richard ^{[13
]}

Chee, Cynthia Bin-Eng ^{[14
]}

Chesire, Lucy ^{[15
]}

Corbett, Elizabeth ^{[16
]}

Dara, Masoud ^{[17
]}

Denholm, Justin ^{[18
]}

de Vries, Gerard ^{[19
]}

Falzon, Dennis ^{[1
]}

Ford, Nathan ^{[20
]}

Gale-Rowe, Margaret ^{[21
]}

Gilpin, Chris ^{[1
]}

Girardi, Enrico ^{[22
]}

Go, Un-Yeong ^{[23
]}

Govindasamy, Darshini ^{[24
]}

Grant, Alison D. ^{[25
]}

Grzemska, Malgorzata ^{[1
]}

Harris, Ross ^{[3
]}

Horsburgh, C. Robert, Jr. ^{[26
]}

Ismayilov, Asker ^{[27
]}

Jaramillo, Ernesto ^{[1
]}

Kik, Sandra ^{[28
,29
]}

Kranzer, Katharina ^{[25
]}

Lienhardt, Christian ^{[1
]}

LoBue, Philip ^{[30
]}

Loennroth, Knut ^{[1
,31
]}

Marks, Guy ^{[32
,33
]}

Menzies, Dick ^{[28
,29
]}

Migliori, Giovanni Battista ^{[34
]}

Mosca, Davide ^{[35
]}

Mukadi, Ya Diul ^{[36
]}

Mwinga, Alwyn ^{[37
]}

Nelson, Lisa ^{[20
]}

Nishikiori, Nobuyuki ^{[38
]}

Oordt-Speets, Anouk ^{[39
]}

Rangaka, Molebogeng Xheedha ^{[2
,40
]}

Reis, Andreas ^{[41
]}

Rotz, Lisa ^{[30
]}

Sandgren, Andreas ^{[42
]}

机构：

[1] WHO, Global TB Programme, 20 Ave Appia, CH-1211 Geneva, Switzerland

[2] UCL, Dept Infect & Populat Hlth, London, England

[3] Publ Hlth England, London, England

[4] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt

[5] Minist Hlth, Natl TB Programme, Brasilia, DF, Brazil

[6] Pedro Kourf Inst Trop Med, Havana, Cuba

[7] Karolinska Inst Solna, Dept Med, Infect Dis Unit, Stockholm, Sweden

[8] Karolinska Univ Hosp, Stockholm, Sweden

[9] Univ Indonesia, Fac Med, Dept Pulmonol & Resp Med, Jakarta, Indonesia

[10] Persahabatan Hosp, Jakarta, Indonesia

[11] Fiocruz MS, Evandro Chagas Natl Inst Infect Dis, BR-21045900 Rio De Janeiro, Brazil

[12] Hosp Nacl Rosales, San Salvador, El Salvador

[13] Johns Hopkins Univ, Ctr TB Res, Baltimore, MD USA

[14] Tan Tock Sang Hosp, Singapore, Singapore

[15] TB Advocacy Consortium, Nairobi, Kenya

[16] London Sch Hyg & Trop Med, Blantyre, Malawi

[17] WHO, Reg Off Europe, Copenhagen, Denmark

[18] Victorian TB Program, Melbourne, Vic, Australia

[19] KNCV TB Fdn, The Hague, Netherlands

[20] WHO, Dept HIV & Global Hepatitis Programme, Geneva, Switzerland

[21] Publ Hlth Agcy Canada, Ottawa, ON, Canada

[22] Ist Nazl Malattie Infett L Spallanzani, Rome, Italy

[23] Korea Ctr Dis Control & Prevent, Dept HIV AIDS & TB Control Korea, Seoul, South Korea

[24] South African Med Res Council, Hlth Syst Res Unit, Cape Town, South Africa

[25] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England

[26] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

[27] Minist Justice, Main Med Dept, Baku, Azerbaijan

[28] McGill Univ, McGill Int TB Ctr, Montreal, PQ, Canada

[29] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada

[30] Ctr Dis Control & Prevent, Atlanta, GA USA

[31] Karolinska Inst, Dept Publ Hlth Sci, Solna, Sweden

[32] Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia

[33] UNSW Australia, Sydney, NSW, Australia

[34] WHO, Collaborating Ctr TB & Lung Dis Fdn S Maugeri, Tradate, Italy

[35] Int Org Migrat, Migrat Hlth Dept, Geneva, Switzerland

[36] US Agcy Int Dev, Div Infect Dis, Bur Global Hlth, Washington, DC 20523 USA

[37] Zambart Project, Lusaka, Zambia

[38] WHO, Reg Off Western Pacific, Manila, Philippines

[39] Paltas Hlth Res & Consultancy BV, Rotterdam, Netherlands

[40] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa

[41] WHO, Knowledge Eth & Res Dept, Geneva, Switzerland

[42] European Ctr Dis Prevent & Control, Stockholm, Sweden

[43] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada

[44] McMaster Univ, Dept Med, GRADE Ctr, Hamilton, ON, Canada

[45] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[46] Minist Hlth, Natl TB Programme, Riyadh, Saudi Arabia

[47] European AIDS Treatment Grp, Brussels, Belgium

[48] Univ Amsterdam, Acad Med Ctr, Dept Global Hlth, NL-1105 AZ Amsterdam, Netherlands

[49] HIV TB & Penal Syst Projects, Moscow, Russia

[50] Minist Hlth, Clin Labs, Nicosia, Cyprus

来源：

EUROPEAN RESPIRATORY JOURNAL | 2015年 / 46卷 / 06期

基金：

英国惠康基金; 美国国家卫生研究院;

关键词：

MULTIDRUG-RESISTANT TUBERCULOSIS; RANDOMIZED CONTROLLED-TRIAL; COST-EFFECTIVENESS; PREVENTIVE THERAPY; CLOSE CONTACTS; FOLLOW-UP; RECOMMENDATIONS; GRADE; ADHERENCE; HIV;

D O I：

10.1183/13993003.01245-2015

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

100201 [内科学];

摘要：

Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3-4 month isoniazid plus rifampicin; or 3-4 month rifampicin alone.

引用

页码：1563 / 1576

页数：14

共 70 条

[1]

GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations [J].

Andrews, Jeff ;

Guyatt, Gordon ;

Oxman, Andrew D. ;

Alderson, Phil ;

Dahm, Philipp ;

Falck-Ytter, Yngve ;

Nasser, Mona ;

Meerpohl, Joerg ;

Post, Piet N. ;

Kunz, Regina ;

Brozek, Jan ;

Vist, Gunn ;

Rind, David ;

Akl, Elie A. ;

Schuenemann, Holger J. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (07) :719-725

[2]

GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength [J].

Andrews, Jeffrey C. ;

Schuenemann, Holger J. ;

Oxman, Andrew D. ;

Pottie, Kevin ;

Meerpohl, Joerg J. ;

Coello, Pablo Alonso ;

Rind, David ;

Montori, Victor M. ;

Brito, Juan Pablo ;

Norris, Susan ;

Elbarbary, Mahmoud ;

Post, Piet ;

Nasser, Mona ;

Shukla, Vijay ;

Jaeschke, Roman ;

Brozek, Jan ;

Djulbegovic, Ben ;

Guyatt, Gordon .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2013, 66 (07) :726-735

[3]

[Anonymous], 2011, US TUB INT GAMM REL

[4]

[Anonymous], GLOB TUB CONTR 2014

[5]

[Anonymous], 2015, WHO/HTM/TB

[6]

[Anonymous], 2014, GLOBAL TUBERCULOSIS

[7]

[Anonymous], 2011, TUB CLIN DIAGN MAN T

[8]

[Anonymous], 2010, GUID ETH TUB PREV CA

[9]

[Anonymous], 2011, Intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings

[10]

[Anonymous], 2013, LAT TUB INF GUID PRI

← 1 2 3 4 5 6 7 →